Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor: Local Sales and Technical Support for Glycofect™ Reagents to Government and University Laboratories

Abstract:
Techulon Inc., the leader in low-toxicity gene delivery has announced a series of expansions to provide enhanced customer support and direct access to the Company's innovative Glycofect transfection reagent in the Northern Virginia/Maryland Technology Corridor. The Company is dedicated to providing compelling technology for the most challenging DNA delivery needs in key research regions where demand for Glycofect and knowledgeable support are required.

Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor: Local Sales and Technical Support for Glycofect™ Reagents to Government and University Laboratories

Blacksburg, VA | Posted on October 6th, 2011

Techulon is pleased Mr. Bill McKay of Olney Biosciences has joined our efforts to provide key account professional services in the Mid-Atlantic region. Mr. McKay will coordinate activities and directly serve clients such as the National Institutes of Health, the National Cancer Institute, and John Hopkins University. "Serving the critical research of NIH and related firms across this biotech community is a privilege and I'm pleased to be working with Techulon to deliver such a quality product," said Bill McKay.

Providing educational information about the Glycofect platform will be the central focus driving Techulon events through the next several months. Techulon is establishing a regular series of seminars and events to provide guidance and training for cell researchers as they begin expanded use of Glycofect in highly critical research programs including Glioma and cortical neurons, dermal fibroblasts and aortic smooth muscle cells. Techulon will roll out its educational initiatives as a focal participant at the October NIH Research Festival at the Institute's main Bethesda campus, and continue to present frequent luncheon workshops throughout 2012. Research team leaders interested in hosting an event should contact Mr. McKay at

"We are gratified that Glycofect is enabling and accelerating research on critical primary cell types and we want to show our commitment to our growing customer base in this important region. Customer awareness and support are top priorities for us as we see the increased use of Glycofect among the research community," said Frank Akers, President of Techulon.

Glycofect is a polymeric nanoparticle-delivery transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used in over 20 countries by government, university and corporate laboratories for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

####

About Techulon Inc.
Techulon, Inc. is a life sciences company headquartered in Blacksburg, VA, with a core capability in novel biodegradable and low toxicity DNA and RNA delivery reagents for cell-based research and therapeutics.

For more information, please click here

Contacts:
Techulon
Frank Akers, President
540-443-9254

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Openings/New facilities/Groundbreaking/Expansion

JPK announces expansion of its global sales and service activities in China and USA April 15th, 2014

Thailand's Next Move on Research and Innovation March 11th, 2014

Beneq and LETI open ALD-dedicated research laboratory in St. Petersburg November 18th, 2013

NTU sets up Southeast Asia’s first nanomedicine research institute - New $60 million institute to focus on diabetes, cardiovascular, ophthalmology and skin therapeutics November 6th, 2013

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE